← Back to headlines
BridgeBio Shares Rise on Reported Settlement in Pfizer Vyndamax Patent Dispute
BridgeBio's stock saw gains following reports of a settlement in a patent dispute involving Pfizer's drug Vyndamax.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
